High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

P. Vainio, L. Lehtinen, Mika Hilvo, T. Mirtti, John Mpindi, Pekka Kohonen, Vidal Fey, K. Ketola, K. Alanen, Merja Perälä, Matej Oresic, Olli Kallioniemi, Kristiina Iljin

    Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

    Original languageEnglish
    Title of host publicationMetabolomics 2010 abstract book
    Subtitle of host publicationBreakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery
    Pages135
    Publication statusPublished - 2010
    MoE publication typeNot Eligible
    EventMetabolomics 2010: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery - Amsterdam, Netherlands
    Duration: 27 Jun 20101 Jul 2010

    Conference

    ConferenceMetabolomics 2010
    CountryNetherlands
    CityAmsterdam
    Period27/06/101/07/10

    Cite this

    Vainio, P., Lehtinen, L., Hilvo, M., Mirtti, T., Mpindi, J., Kohonen, P., Fey, V., Ketola, K., Alanen, K., Perälä, M., Oresic, M., Kallioniemi, O., & Iljin, K. (2010). High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. In Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery (pp. 135) http://fiehnlab.ucdavis.edu/downloads/staff/kind/metabolomics_2010_abstract_book.pdf